Exact Mass: 635.2591152
Exact Mass Matches: 635.2591152
Found 103 metabolites which its exact mass value is equals to given mass value 635.2591152,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
GW 6471
PA(2:0/LTE4)
PA(2:0/LTE4) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/LTE4), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(LTE4/2:0)
PA(LTE4/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(LTE4/2:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
13alpha,16alpha,20-triacetoxy-14alpha-benzoyloxy-himbosan-18-oic acid methyl ester|13alpha,16alpha,20-Triacetoxy-14alpha-benzoyloxy-himbosan-18-saeure-methylester|Himbosin
C35H41NO10 (635.2730326000001)
Phe Phe His Trp
Phe Phe Trp His
Phe His Phe Trp
Phe His Trp Phe
Phe Trp Phe His
Phe Trp His Phe
His Phe Phe Trp
His Phe Trp Phe
His Met Trp Tyr
His Met Tyr Trp
His Trp Phe Phe
His Trp Met Tyr
His Trp Tyr Met
His Tyr Met Trp
His Tyr Trp Met
Lys Tyr Tyr Tyr
C33H41N5O8 (635.2954986000001)
Met His Trp Tyr
Met His Tyr Trp
Met Asn Trp Trp
Met Trp His Tyr
Met Trp Asn Trp
Met Trp Trp Asn
Met Trp Tyr His
Met Tyr His Trp
Met Tyr Trp His
Asn Met Trp Trp
Asn Trp Met Trp
Asn Trp Trp Met
Gln Tyr Tyr Tyr
Trp Phe Phe His
Trp Phe His Phe
Trp His Phe Phe
Trp His Met Tyr
Trp His Tyr Met
Trp Met His Tyr
Trp Met Asn Trp
Trp Met Trp Asn
Trp Met Tyr His
Trp Asn Met Trp
Trp Asn Trp Met
Trp Trp Met Asn
Trp Trp Asn Met
Trp Tyr His Met
Trp Tyr Met His
Tyr His Met Trp
Tyr His Trp Met
Tyr Lys Tyr Tyr
C33H41N5O8 (635.2954986000001)
Tyr Met His Trp
Tyr Met Trp His
Tyr Gln Tyr Tyr
Tyr Trp His Met
Tyr Trp Met His
Tyr Tyr Lys Tyr
C33H41N5O8 (635.2954986000001)
Tyr Tyr Gln Tyr
Tyr Tyr Tyr Lys
C33H41N5O8 (635.2954986000001)
Tyr Tyr Tyr Gln
(+)-1,2-BIS((2S,5S)-2,5-DIMETHYLPHOSPHOLANO)BENZENE(CYCLOOCTADIENE)RHODIUM(I)TETRAFLUOROBORATE
C28H47BF4P2Rh (635.2237029999999)
[(2S,3R,4S,5S,6R)-4-azaniumyl-2-[(1S,2S,3R,4S,6R)-4-azaniumyl-3-[(2R,3R,6S)-3-azaniumyl-6-(azaniumylmethyl)oxan-2-yl]oxy-6-[[(2S)-4-azaniumyl-2-hydroxybutanoyl]amino]-2-hydroxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-3-yl] phosphate
ethyl N-[3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-[[(E)-4-oxo-4-[4-(trifluoromethyl)phenyl]but-2-en-2-yl]amino]propyl]carbamate
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp-O(CH2)2S(CH2)2CONH2
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-{4-[(E)-2-(2,4-dihydroxyphenyl)ethenyl]-2,6-dihydroxyphenyl}-3-hydroxy-3-methylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C29H37N3O11S (635.2148692000001)
DDHepalpha1-2DDHepalpha1-2alpha1-3DDHepalphaO[CH2]3NH2
(2e)-2-[4,5-dihydroxy-2-(2-{[2-(4-hydroxyphenyl)ethyl]-c-hydroxycarbonimidoyl}ethyl)phenyl]-3-(4-hydroxy-3,5-dimethoxyphenyl)-n-{4-[(1-hydroxyethylidene)amino]butyl}prop-2-enimidic acid
(1r,2r,3r,4s,5r,6s,7s,8s,9r,11r,12s,14r,17r,18s)-4,6,18-tris(acetyloxy)-7-formyl-17-hydroxy-7,10-dimethyl-15-methylidene-13-oxo-10-azahexacyclo[7.7.1.1²,¹⁴.0¹,¹².0³,⁸.0³,¹¹]octadecan-5-yl benzoate
(2s)-2-{[(2s)-1,3-dihydroxy-2-({hydroxy[(4s)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazol-4-yl]methylidene}amino)propylidene]amino}-n-[(1s)-1-{[(3r)-1-hydroxy-2-oxopiperidin-3-yl]-c-hydroxycarbonimidoyl}ethyl]-5-(n-hydroxyformamido)pentanimidic acid
aconitum coreanum alkaloid
C35H41NO10 (635.2730326000001)
{"Ingredient_id": "HBIN014584","Ingredient_name": "aconitum coreanum alkaloid","Alias": "NA","Ingredient_formula": "C35H41NO10","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7189","PubChem_id": "NA","DrugBank_id": "NA"}